–  Compelling PAX-D results guided Alto's acquisition of ALTO-207, designed to induce rapid antidepressant effects while mi...

HC Wainwright & Co. analyst Patrick Trucchio reiterates Alto Neuroscience (NYSE:ANRO) with a Buy and maintains $10 price...

Demonstrated target engagement and response prediction for ALTO-203 by theta/beta ratio, a commonly used EEG index of cortical ...

Alto Neuroscience acquires Chase's treatment-resistant depression drug portfolio for $1.75 million upfront; early data show...

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of ...

Wedbush analyst Laura Chico reiterates Alto Neuroscience (NYSE:ANRO) with a Neutral and maintains $4 price target.

Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.6...

– Identified and prospectively replicated an EEG-based biomarker for placebo response in MDD –– New data strengthen the mechani...

HC Wainwright & Co. analyst Patrick Trucchio initiates coverage on Alto Neuroscience (NYSE:ANRO) with a Buy rating and a...

Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(2.50) per share which beat the analyst consensus estimate of $(2.5...